Cevimeline
Cevimeline, Evoxac (cevimeline) is a small molecule pharmaceutical. Cevimeline was first approved as Evoxac on 2000-01-11. It is used to treat xerostomia in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M4, and muscarinic acetylcholine receptor M3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| stomatognathic diseases | D009057 |
Trade Name
FDA
EMA
Cevimeline, Evoxac (discontinued: Cevimeline)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cevimeline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EVOXAC | Cosette Pharmaceuticals | N-020989 RX | 2000-01-11 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cevimeline | ANDA | 2024-02-08 |
| cevimeline hydrochloride | ANDA | 2024-12-30 |
| evoxac | New Drug Application | 2022-09-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| xerostomia | — | D014987 | K11.7 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Xerostomia | D014987 | — | K11.7 | 2 | — | — | 1 | 1 | 4 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | — | — | — | — | 1 | — | — | 1 |
| Radiation effects | D011830 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | 1 | — | — | — | 1 |
| Dry eye syndromes | D015352 | — | H04.12 | — | 1 | — | — | — | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cevimeline |
| INN | cevimeline |
| Description | Cevimeline (trade name Evoxac) is a synthetic analog of the natural alkaloid muscarine with a particular agonistic effect on M1 and M3 receptors. It is used in the treatment of dry mouth and Sjögren's syndrome.
|
| Classification | Small molecule |
| Drug class | cholinergic agonists (arecoline derivatives used in treatment of Alzheimer's disease |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1OC2(CS1)CN1CCC2CC1 |
Identifiers
| PDB | — |
| CAS-ID | 107233-08-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL168815 |
| ChEBI ID | — |
| PubChem CID | 83898 |
| DrugBank | DB00185 |
| UNII ID | K9V0CDQ56E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CHRM2
CHRM2
CHRM1
CHRM1
CHRM4
CHRM4
CHRM3
CHRM3
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cevimeline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 638 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
251 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use